Short Bowel Syndrome Market in the 7MM is expected to grow from USD 2,450 million in 2025 to USD 3,994 million in 2034, estimates DelveInsight

DelveInsight's "Short Bowel Syndrome Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Short Bowel Syndrome Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Short Bowel Syndrome Market Forecast @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Short Bowel Syndrome Market Report
• In October 2025, Hanmi Pharmaceutical Company Limited announced a Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF).
• In 2024, the US accounted for the highest number of prevalent SBS cases in the 7MM, with approximately 14,000 cases, followed by the EU4 and the UK. Surgical complications, in particular, continue to be a leading contributor to the prevalence of SBS in the country.
• Short bowel syndrome is more common in females as compared to males. In the United States, more than 67% of short bowel syndrome patients were females. Anatomical differences are a key factor; women typically start with a shorter baseline length of the small intestine than men, so extensive resections leave them at greater risk for developing SBS after bowel surgery.
• In the United States, around 29% and ~24% short bowel syndrome cases were caused by surgical complications and mesenteric infarction, respectively, in 2024. SBS primarily arises from surgical complications, mesenteric ischemia, Crohn's disease, neoplasms, and radiation enteritis, with surgical complications and ileus representing the largest share of cases.
• In EU4 and the UK, Germany accounted for the highest prevalent cases of short bowel syndrome, while Spain accounted for the least prevalent cases in 2024.
• The leading Short Bowel Syndrome Companies such as Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others.
• Promising Short Bowel Syndrome Therapies such as Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others.

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Epidemiology
• Total Prevalence of Short Bowel Syndrome
• Prevalent Cases of Short Bowel Syndrome by severity
• Gender-specific Prevalence of Short Bowel Syndrome
• Diagnosed Cases of Episodic and Chronic Short Bowel Syndrome

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Short Bowel Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Short Bowel Syndrome Therapies and Companies
• Glepaglutide: Zealand Pharma
• Apraglutide: Ironwood Pharmaceuticals
• HM15912: Hanmi Pharmaceutical
• Teduglutide: Shire
• Pancreatic Enzyme: AbbVie
• HM15912 Active: Hanmi Pharma
• Somatropin: EMD Serono
• ZP1848: Zealand Pharma
• FE203799: VectivBio AG
• Clinolipid: Baxter Healthcare

Discover more about therapies set to grab major Short Bowel Syndrome market share @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Market Strengths
• In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Market Opportunities
• Several organizations are actively working to provide information and increase awareness of such disorders.
• There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of the Short Bowel Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Short Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Short Bowel Syndrome Market Access and Reimbursement

To know more about Short Bowel Syndrome companies working in the treatment market, visit @ Short Bowel Syndrome Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Short Bowel Syndrome Market Report Introduction
2. Executive Summary for Short Bowel Syndrome
3. SWOT analysis of Short Bowel Syndrome
4. Short Bowel Syndrome Patient Share (%) Overview at a Glance
5. Short Bowel Syndrome Market Overview at a Glance
6. Short Bowel Syndrome Disease Background and Overview
7. Short Bowel Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Short Bowel Syndrome
9. Short Bowel Syndrome Current Treatment and Medical Practices
10. Short Bowel Syndrome Unmet Needs
11. Short Bowel Syndrome Emerging Therapies
12. Short Bowel Syndrome Market Outlook
13. Country-Wise Short Bowel Syndrome Market Analysis (2020-2034)
14. Short Bowel Syndrome Market Access and Reimbursement of Therapies
15. Short Bowel Syndrome Market Drivers
16. Short Bowel Syndrome Market Barriers
17. Short Bowel Syndrome Appendix
18. Short Bowel Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.